<i>EGFR</i>遺伝子変異陽性非小細胞肺がんにおけるgefitinibの治療効果に対する制酸剤併用の影響

DOI Web Site 参考文献1件

書誌事項

タイトル別名
  • Effects of Antacids on Clinical Efficacy of Gefitinib in Patients with <i>EGFR</i> Mutation-Positive Non-small Cell Lung Cancer

抄録

<p>The absorption of gefitinib is dependent on gastric pH. However, an increase in gastric pH via the use of antacids such as proton pump inhibitors (PPI) and histamine H2 receptor antagonists may reduce the bioavailability and efficacy of gefitinib.</p><p>In this study, we report the influence of the concurrent use of antacids with gefitinib on the efficacy in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Our subjects were 68 patients with NSCLC who were treated with gefitinib at our hospital between 2008 and 2015.</p><p>In the study, we compared time to treatment failure (TTF), overall survival (OS), response rate, disease control rate and adverse effect rates in patients receiving antacids in combination as well as (AC; n = 29) with those only receiving gefitinib (no AC; n = 34).</p><p>The patients in the AC group exhibited a significant difference in TTF (409 days (95％CI: 1.00-4.22) vs 901 days (95％CI: 0.24-0.99), P = 0.0492) as compared to the no AC group. But then the OS, response rate, disease control rate and adverse effects rate were not significant between each group. Therefore, this study suggests that, as long as the combination of gefitinib with antacids is avoided, the combination with antacids should not impair the clinical efficacy of gefitinib. From the results of the sub-analysis, this study suggests that, in particular men, less than 75 years old, PS≧2, pulmonary metastasis, it is preferable to avoid the combination of gefitinib and antacids.</p>

収録刊行物

  • 医療薬学

    医療薬学 43 (3), 145-153, 2017

    一般社団法人日本医療薬学会

参考文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ